FDA approves pembrolizumab plus axitinib for advanced RCC
(HealthDay)—The combination of pembrolizumab and axitinib has been approved as a first-line treatment in advanced renal cell carcinoma (RCC), the […]
» Read moreHome »
nohealthproblemsnews.com
Home »
(HealthDay)—The combination of pembrolizumab and axitinib has been approved as a first-line treatment in advanced renal cell carcinoma (RCC), the […]
FDA approves pembrolizumab plus axitinib for advanced RCC